Decoy Therapeutics (DCOY)
NASDAQ:DCOY
Top Page
Decoy Therapeutics
(NASDAQ:DCOY)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.00
▼(-3.23% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by weak financial performance (no sustained revenue, ongoing losses and cash burn) and bearish technicals (below major moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend, partially offset by the positive corporate event of regaining Nasdaq compliance, though monitoring status remains a risk.
Positive Factors
Low leverage and improved capitalization
Near-zero debt and a sharp equity rebound in 2025 materially reduce financial fragility. Lower leverage increases flexibility to fund R&D or partner programs without immediate refinancing, improving the company’s ability to advance its pipeline and survive funding cycles over the medium term.
Negative Factors
Absent sustained revenue
The lack of sustained revenue limits operating leverage and obscures a commercial path. Without predictable product income, the company must rely on external financing to support operations and trials, reducing visibility to profitability and constraining long-term planning and reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and improved capitalization
Near-zero debt and a sharp equity rebound in 2025 materially reduce financial fragility. Lower leverage increases flexibility to fund R&D or partner programs without immediate refinancing, improving the company’s ability to advance its pipeline and survive funding cycles over the medium term.
Read all positive factors
Decoy Therapeutics (DCOY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.23M
Dividend YieldN/A
Average Volume (3M)356.88K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS Growth68.08%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-2.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.87
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$2.50Price Target Upside-59.68% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Decoy Therapeutics Business Overview & Revenue Model
Company Description
Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that tar...
How the Company Makes Money
null...
Decoy Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.52M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.61M | -5.73M | -12.88M | -22.97M | -12.79M |
| Net Income | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
Balance Sheet | |||||
| Total Assets | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Cash, Cash Equivalents and Short-Term Investments | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Total Debt | 0.00 | 221.87K | 289.64K | 0.00 | 0.00 |
| Total Liabilities | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Stockholders Equity | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
Cash Flow | |||||
| Free Cash Flow | -4.83M | -4.53M | -12.85M | -19.10M | -10.20M |
| Operating Cash Flow | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Investing Cash Flow | 764.74K | 0.00 | 0.00 | -1.50M | 0.00 |
| Financing Cash Flow | 12.34M | 1.06M | 6.64M | 1.99M | 28.30M |
Decoy Therapeutics Technical Analysis
Negative
6.20
Price Trends
7.74
Negative
8.64
Negative
43.24
Negative
Market Momentum
-0.61
Positive
39.11
Neutral
30.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCOY, the sentiment is Negative. The current price of 6.2 is below the 20-day moving average (MA) of 6.78, below the 50-day MA of 7.74, and below the 200-day MA of 43.24, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 39.11 is Neutral, neither overbought nor oversold. The STOCH value of 30.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCOY.
Decoy Therapeutics Risk Analysis
Decoy Therapeutics disclosed 44 risk factors in its most recent earnings report. Decoy Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Decoy Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $2.05M | -0.20 | ― | ― | 178.82% | -4121.10% | |
43 Neutral | $3.23M | -0.30 | -139.55% | ― | ― | 68.08% | |
43 Neutral | $1.40M | -0.19 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.95M | -0.17 | -168.95% | ― | ― | 90.27% | |
| ― | $554.34K | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
DCOY
Decoy Therapeutics
6.20
-123.40
-95.22%
BDRX
Biodexa Pharmaceuticals
3.25
-69.75
-95.55%
QCLS
Q/C Technologies
3.70
-23.30
-86.30%
SCNI
Scinai Immunotherapeutics
0.59
-1.33
-69.22%
OGEN
Oragenics
0.66
-4.93
-88.28%
ONCO
Onconetix
0.91
-26.63
-96.70%
Decoy Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split
Positive
Apr 2, 2026
Decoy Therapeutics has regained compliance with Nasdaq’s minimum bid price requirement after a period of deficiency that began with a notice on December 31, 2025, when its shares traded below $1.00 for 30 consecutive business days. Following...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Decoy Therapeutics Announces Reverse Stock Split to Maintain Listing
Neutral
Mar 5, 2026
Decoy Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on AI-enabled peptide conjugate therapeutics for respiratory viruses and gastrointestinal cancers, has built a diversified funding base from institutional investors and...
Shareholder MeetingsStock Split
Decoy Therapeutics Shareholders Approve Plan and Reverse Split
Neutral
Feb 25, 2026
On February 24, 2026, Decoy Therapeutics Inc. held a virtual special meeting of stockholders at which a quorum of 2,696,758 common shares was present or represented by proxy. Stockholders voted on an equity incentive plan, a reverse stock split, a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.